Journal of the Formosan Medical Association · 2020 · 55 citations · 24 references
Life SciencesOncologyPharmacologyApoptosisDna RepairOral OncologyApoptosis In CancerDna Damage SignalingDna Damage-induced ApoptosisDna Repair In CarcinogenesisOral Anticancer AgentsOral CarcinogenesisAnticancer ActivityCell Cycle AnalysisCell Cycle InhibitorsCellular Senescence MarkersCyclin-dependent Kinase 4 InhibitorsCyclin-dependent Kinase 4/6 InhibitorsDna Damage Repair PathwaysDrug-induced Dna Damage
BACKGROUND/PURPOSE: Palbociclib is an FDA-approved cyclin-dependent kinase (CDK) 4/6 inhibitor that has been clinically proven to be effective in breast cancer. However, its use in oral cancer is not well researched. In this study, we investigated the inhibitory activity of palbociclib against oral squamous cell carcinoma (OSCC) cells and explored the mechanism of inhibition. METHODS: The effects of palbociclib on the cytotoxicity of OSCC cells were determined by MTT and colony formation assays. β-Galactosidase staining and cell-cycle analysis were used to determine palbociclib-induced cellular senescence and apoptosis of OSCC cells. Wound healing and transwell assays were performed to assess the effects of palbociclib treatment on migration and invasion ability of OSCC cells. Whole transcriptome sequencing was conducted to show the relationship between DNA damage repair of OSCC cells and palbociclib treatment. Palbociclib-induced DNA damage and repair capacity of OSCC cells were confirmed by comet assay and immunofluorescence confocal microscopy. Western blotting was used to verify the palbociclib-mediated changes in the CDK/pRB/c-Myc/CDC25A pathway. Finally, in vitro findings were tested in a mouse xenograft model. RESULTS: Our results showed that palbociclib can significantly inhibit the growth, migration, and invasive ability of OSCC cells and can accelerate cellular senescence and apoptosis. We found that palbociclib induced DNA damage and p21 expression through the p53-independent pathway, thereby downregulating c-Myc and CDC25A expression to inhibit cell cycle progression. In addition, palbociclib downregulated RAD51 expression to inhibit DNA damage repair ability of OSCC cell. CONCLUSION: Palbociclib was found to have anti-oral squamous cell carcinoma activity and to simultaneously induce DNA damage and inhibit its repair, and to accelerated cellular senescence and apoptosis.
24
César Rivera · PubMed · 2015 · 830 citations · Full text
The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases
Bo Wang, Shu Zhang, Kai Yue et al. · Chinese Journal of Cancer · 2013 · 331 citations · Full text
Metastasis from oral cancer: an overview.
Juliana Noguti, Carolina Foot Gomes de Moura, Gustavo Protasio Pacheco de Jesus et al. · PubMed · 2013 · 272 citations · Full text
Dentistry, Cancer Biology, Oncology +17